Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Zeev's Turnips - No Politics -- Ignore unavailable to you. Want to Upgrade?

To: Zeev Hed who wrote (23880)	1/23/2002 7:57:13 AM
From: orkrious	Respond to of 99280

Zeev, Stpehen Roach talks about America's growing current account deficit as a percent of GDP. He must read this thread. His "double dip" thesis was printed here first, too. <G> morganstanley.com

To: Zeev Hed who wrote (23880)	1/23/2002 8:13:07 AM
From: wgh613	Respond to of 99280

ENMD, DJ Allergan, EntreMed Form Alliance For Eye Diseases 01/23/2002 Dow Jones News Services (Copyright © 2002 Dow Jones & Company, Inc.) (MORE) DOW JONES NEWS 01-23-02 12:03 AM DJ Allergan/EntreMed Alliance -2: EntreMed To Get Up To $41M IRVINE, Calif. (Dow Jones)--Allergan Inc. (AGN) and EntreMed Inc. (ENMD) confirmed the formation of a five-year alliance to develop and commercialize small molecule angiogenic inhibitors to treat and prevent eye disease. EntreMed will receive up to $41 million in initial cash payments, equity investments and milestone payments. The company also will receive development funding and royalties on worldwide sales of future products resulting from the alliance. In a press release Wednesday, EntreMed said Allergan will receive an exclusive worldwide license to commercialize Panzem, EntreMed's small molecule, for opthalmologic uses. The companies will co-develop Panzem to treat age-related macular degeneration. The agreement also calls for co-promotion between the companies. If Allergan chooses to develop any of EntreMed's other small molecules, the terms of the agreement will apply to each clinical candidate. Panzem also treats cancer, Wednesday's Wall Street Journal said. Pharmaceutical company Allergan, which agreed Tuesday to spin off its optical-device business, had 2001 revenue of $1.69 billion. For the year ended Dec. 31, 2000, biopharmaceutical company EntreMed had revenue of $3.7 million. For the nine months ended Sept. 30, 2000, EntreMed revenue was $1.7 million. -Lisa Reynolds; Dow Jones Newswires; 201-938-5400 (END) DOW JONES NEWS 01-23-02 05:19 AM